{
    "clinical_study": {
        "@rank": "28678", 
        "arm_group": [
            {
                "arm_group_label": "Liothyronine Sodium/Triiodothyronine", 
                "arm_group_type": "Active Comparator", 
                "description": "bolus administration of Liothyronine Sodium/Triiodothyronine (Triostat) immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses, will be safe and will result in significant improvements in postoperative and clinical outcome parameters and cardiac contractile function."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "bolus administration of Placebo immediately prior to CPB institution and after removal of aortic cross clamp, followed by repeated boluses"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study to determine the safety and efficacy of liothyronine sodium/triiodothyronine\n      (Triostat), a synthetic thyroid hormone, when given to infants with congenital heart disease\n      during cardiopulmonary bypass surgery."
        }, 
        "brief_title": "Study of Triostat in Infants During Heart Surgery", 
        "completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "condition": "Heart Defects, Congenital", 
        "condition_browse": {
            "mesh_term": [
                "Congenital Abnormalities", 
                "Heart Defects, Congenital"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients will be randomized to receive study drug or placebo and randomization will occur\n      stratified to each diagnostic category. All patients undergo preoperative echocardiograms to\n      provide preoperative cardiac function data. The study drug or placebo will be provided in\n      the operating room as an iv bolus just prior to cardiopulmonary bypass and as a bolus\n      delivered on release of the aortic cross-clamp. This will be followed by iv for 12 hours.\n      Operative data will be collected including CPB time, aortic cross-clamp time, length and\n      degree of hypothermia. These data will be extracted from the anesthesia record."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Diagnosis of one of the following:\n\n          -  Ventricular septal defect (VSD)\n\n          -  Infant coarctation of the aorta\n\n          -  Transposition of the great arteries\n\n          -  Tetralogy of Fallot\n\n          -  Complete atrioventricular canal defect\n\n          -  Hypoplastic left heart, including patients who undergo a Norwood type procedure for\n             aortic or mitral atresia\n\n        Patient must be scheduled for surgery.\n\n        Exclusion criteria:\n\n          -  Certain additional defects and/or requirement for additional surgery."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "2 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "195", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 5, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00027417", 
            "org_study_id": "FD-R-1971-01", 
            "secondary_id": "FD-R-001971-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Liothyronine Sodium/Triiodothyronine", 
                    "Placebo"
                ], 
                "intervention_name": "Liothyronine sodium/triiodothyronine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Liothyronine Sodium/Triiodothyronine", 
                    "Placebo"
                ], 
                "intervention_name": "Cardiopulmonary bypass and cardiac surgery", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Congenital heart defects", 
            "Hypoplastic left heart syndrome", 
            "Complete atrioventricular canal defect", 
            "Triostat", 
            "Cardiac surgery"
        ], 
        "lastchanged_date": "August 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seattle", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98105"
                }, 
                "name": "Children's Hospital and Regional Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Triostat in Children During CardioPulmonary Bypass (CPB)", 
        "overall_official": {
            "affiliation": "Seattle Childrens Hospital", 
            "last_name": "Michael Portman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2007", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Reducing the length of ventilatory support minimizes other postoperative complications, which can contribute to morbidity.", 
            "measure": "duration of mechanical ventilation after cardiopulmonary bypass.", 
            "safety_issue": "Yes", 
            "time_frame": "0 to 72 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00027417"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seattle Children's Hospital", 
            "investigator_full_name": "Michael Portman", 
            "investigator_title": "Cardiologist", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "Need for mechanic circulatory support, fluid balance (intake and output); urine output\nEchocardiographic measures to include end-systolic wall stress/fractional shortening ratio\nMyocardial performance index (Doppler derived), cardiac index (Doppler derived)\nHeart rate, blood pressure and central venous pressure\nFree and total T3 levels\nOthers: All medications including inotropic agents will be recorded with respect to time initiated, terminated, and dosage will be recorded for exploratory analyses.", 
            "measure": "Assess other parameters", 
            "safety_issue": "Yes", 
            "time_frame": "0 to 72 hrs"
        }, 
        "source": "Seattle Children's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Michael Portman", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }, 
    "geocoordinates": {
        "Children's Hospital and Regional Medical Center": "47.606 -122.332"
    }
}